GlassScriptPhysician profile
Sushma Pant
NPI 1083668248
$7,517.91
in general payments reported to CMS, 2019-2025
36 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $502 · 2021: $986 · 2022: $937 · 2023: $1,427 · 2024: $868 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,489 · Education: $32.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,488.61 |
| Education | $32.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,146.60 | 2021-2025 | Enhertu, Calquence, Lynparza |
| Incyte Corporation | $566.20 | 2019-2023 | Jakafi, Pemazyre |
| Amgen INC. | $448.35 | 2020-2025 | Lumakras |
| E.R. Squibb & Sons, L.L.C. | $445.88 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $439.87 | 2020-2025 | Rybrevant, Carvykti, Erleada |
| Astellas Pharma US INC | $425.86 | 2021-2025 | Vyloy, Padcev |
| Novartis Pharmaceuticals Corporation | $405.74 | 2019-2025 | |
| Genentech USA, INC. | $361.01 | 2019-2024 | Polivy, Phesgo, Venclexta |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Daiichi Sankyo INC. | $290.49 | 2021-2025 | Injectafer, Enhertu, Datroway |
| Novocure Gmbh | $250.00 | 2022 | |
| Seagen INC. | $241.34 | 2022-2023 | Tukysa, Tivdak |
| Merck Sharp & Dohme LLC | $240.08 | 2019-2024 | Keytruda |
| Array Biopharma INC | $218.52 | 2019-2025 | Mektovi, Braftovi, Paxlovid |
| Eisai INC. | $206.55 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $170.07 | 2020-2025 | |
| Glaxosmithkline, LLC. | $150.91 | 2024-2025 | Zejula, Ojjaara |
| Jazz Pharmaceuticals INC. | $149.99 | 2023 | |
| Pfizer INC. | $149.30 | 2021-2024 | |
| Genzyme Corporation | $124.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $109.15 | 2024-2025 | Libtayo |
| Kite Pharma, INC. | $107.14 | 2019 | |
| Tempus Ai, INC | $98.00 | 2024 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $69.11 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.08 | 2019 | |
| Lilly USA, LLC | $51.91 | 2024 | Jaypirca |
| Celgene Corporation | $51.27 | 2022-2025 | Reblozyl |
| Taiho Oncology, INC. | $29.86 | 2024 | |
| Myriad Genetic Laboratories, INC. | $23.95 | 2022 | |
| Novocure INC. | $23.20 | 2025 | Optune Lua (Novottf-200t) |
| Sobi, INC | $22.86 | 2022 | |
| Coherus Oncology, INC. | $19.02 | 2024 | |
| Clovis Oncology, INC. | $18.12 | 2022 | |
| Dendreon Pharmaceuticals LLC | $15.95 | 2022 | |
| Sun Pharmaceutical Industries INC. | $15.62 | 2023 | Yonsa, Odomzo |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushma Pant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.